1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Morgan Stanley said its Board will raise the quarterly common stock dividend to $1.15 per share from $1.00, starting with the dividend expected to be declared in the third quarter of 2026, and reauthorized a multi-year share repurchase program of up to $20 billion with no set expiration date. The Federal Reserve's 2026 stress test results do not change the firm's 4.3% Stress Capital Buffer requirement, which the firm expects to remain in place until October 1, 2027.
Quarterly dividend rises 15 cents, from $1.00 to $1.15 per share, starting with the third quarter of 2026 declaration.
Share repurchase program of up to $20 billion reauthorized, beginning in the third quarter of 2026, with no set expiration date.
Stress Capital Buffer requirement stays at 4.3%; the firm's aggregate U.S. Basel III CET1 ratio is 11.8%, versus 15.1% as of March 31, 2026.
Goldman Sachs said the Federal Reserve released its 2026 Comprehensive Capital Analysis and Review results and that the firm remains well capitalized. The firm intends to raise its common dividend from $4.50 to $5.00 per share starting July 1, 2026, subject to Board approval at its scheduled third quarter meeting.
Planned dividend rise from $4.50 to $5.00 per share, effective July 1, 2026, subject to Board approval at the third quarter meeting
Dividend increase is 11% above current levels and 25% above the prior year, per the filing
Stress capital buffer stays at 3.4% through September 30, 2027; CET1 requirement stays at 11.4%
Jefferies reported net earnings attributable to common shareholders of $226 million, or $1.02 per diluted share, for the quarter ended May 31, 2026, up from $88 million, or $0.40 per share, a year earlier. Net revenues rose to $2.21 billion from $1.63 billion, led by investment banking and a record quarter for Equities, and the board raised the share buyback authorization to $250 million. The figures are preliminary and may be revised in the Form 10-Q the company expects to file on or about July 9, 2026.
Net revenues of $2.21 billion, compared with $1.63 billion in the prior-year quarter
Investment banking net revenues of $1.21 billion, up 57% from the prior-year quarter; Equities net revenues a record $601 million, up 14%
Repurchased 4.0 million shares for $197 million during the quarter; board raised buyback authorization to $250 million
Quarterly cash dividend of $0.40 per share, payable August 28, 2026 to holders of record on August 18, 2026
JPMorgan Chase said its Board intends to raise the quarterly common stock dividend to $1.65 per share from $1.50 for the third quarter of 2026, subject to later Board approval. The Board also authorized a new $50 billion common share repurchase program effective July 1, 2026, to be used at management's discretion. The Firm's Stress Capital Buffer requirement of 2.5% and its 11.5% CET1 capital ratio requirement remain unchanged, which matters to shareholders because it signals more capital returned to them under current rules.
Intended quarterly dividend of $1.65 per share, up from $1.50, for the third quarter of 2026
New $50 billion common share repurchase program effective July 1, 2026
Stress Capital Buffer requirement of 2.5% unchanged through September 30, 2027
Standardized CET1 capital ratio requirement including buffers remains 11.5%
Micron reported record fiscal third-quarter 2026 results for the quarter ended May 28, 2026, with revenue of $41.46 billion, up from $9.30 billion a year earlier, and GAAP net income of $28.24 billion, or $24.67 per diluted share. The company guided fiscal fourth-quarter revenue to $50.0 billion plus or minus $1.0 billion and GAAP diluted EPS to $30.73 plus or minus $1.00, and declared a $0.15 quarterly dividend.
Q3 revenue of $41.46 billion versus $23.86 billion in the prior quarter and $9.30 billion a year earlier
GAAP diluted EPS of $24.67; non-GAAP diluted EPS of $25.11
Q4 outlook: revenue of $50.0 billion ± $1.0 billion; GAAP diluted EPS of $30.73 ± $1.00
Quarterly dividend of $0.15 per share payable July 21, 2026, to holders of record as of July 6, 2026
Paychex reported fiscal fourth-quarter results for the quarter ended May 31, 2026, with total revenue up 12% to $1.6 billion and diluted earnings per share up 43% to $1.17 versus $0.82 a year earlier. For fiscal 2027, the company expects adjusted diluted earnings per share to grow 7% to 9% and total revenue to grow 5% to 6%, which shareholders can compare with the fiscal 2026 growth rates in the filing.
Q4 total revenue rose 12% to $1.6 billion; operating income rose 40% to $604.7 million
Q4 diluted EPS was $1.17 versus $0.82; adjusted diluted EPS was $1.32 versus $1.19
Fiscal 2027 outlook: total revenue growth of 5% to 6%; adjusted diluted EPS growth of 7% to 9%
Returned $2.2 billion to shareholders in fiscal 2026, including $611.0 million in share repurchases
Absci reported interim blinded Phase 1 data for ABS-201, an investigational antibody for androgenetic alopecia, showing study drug appeared well tolerated across 32 participants in four single ascending dose cohorts as of a June 8, 2026 data cutoff. The estimated half-life of at least 65 days is preliminary and supports a possible dosing schedule of two or three injections over six months, pending further follow-up. The filing contains no financial results or guidance, and the company expects interim proof-of-concept data in the second half of 2026.
Interim data covers 32 healthy adult participants across four single ascending dose cohorts, with a June 8, 2026 data cutoff
No serious adverse events reported as of the cutoff; treatment-related adverse events were reported in 5 participants and all were mild
Estimated half-life for ABS-201 is at least 65 days, pending confirmation through continued follow-up
Interim proof-of-concept data expected in the second half of 2026; full proof-of-concept data expected in early 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.